Filling the gap: How off-patent medicines can improve the equity and quality of cancer care

European Parliament report calls for increased use of… 24 November 2021 Open
From disruption to care for cancer patients 5 September 2022 Biosimilar medicines are biologic medicines that can be used safely…
The off-patent medicines industry is a vital part of the… 30 June 2022 Health systems face tremendous challenges across Europe. The management of…
Essential medicines must be included in EU industrial policy… 3 March 2022 Political ambitions to strengthen EU supply chain resilience following the…